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Background. High-mobility group box-1 (HMGB-1) protein is released during “late sepsis” by activated monocytes. We
investigated whether systemic HMGB-1 levels are associated with indices of monocytic activation/function in patients with
sepsis-induced immunosuppression. Methodology. 36 patients (31 male, 64 ± 14 years) with severe sepsis/septic shock and
monocytic deactivation (reduced mHLA-DR expression and TNF-α release) were assessed in a subanalysis of a placebo-controlled
immunostimulatory trial using GM-CSF. HMGB-1 levels were assessed over a 9-day treatment interval. Data were compared
to standardized biomarkers of monocytic immunity (mHLA-DR expression, TNF-α release). Principle ﬁndings.H M G B - 1l e v e l s
were enhanced in sepsis but did not diﬀer between treatment and placebo groups at baseline (14.6 ± 13.5v e r s u s1 2 .5 ± 11.5
ng/ml, P = .62). When compared to controls, HMGB-1 level increased transiently in treated patients at day 5 (27.8 ± 21.7v e r s u s
11.0 ± 14.9, P = .01). Between group diﬀerences were not noted at any other point of assessment. HMGB-1 levels were not
associated with markers of monocytic function or clinical disease severity. Conclusions. GM-CSF treatment for sepsis-induced
immunosuppression induces a moderate but only transient increase in systemic HMGB-1 levels. HMGB-1 levels should not be
used for monitoring of monocytic function in immunostimulatory trials as they do not adequately portray contemporary changes
in monocytic immunity.
1.Introduction
High-mobilitygroupbox-1(HMGB-1)protein,alsoreferred
to as amphoterin, is a highly conserved protein that is
constitutively expressed in immune cells including mono-
cyte/macrophages,dendriticcells,andneutrophils.HMGB-1
is known as a nuclear DNA-binding protein that is required
for transcriptional regulation and gene expression [1, 2].
In sepsis, HMGB-1 is typically released by activated
innate immune cells in the later phase of the disease [2–4].
Here, HMGB-1 release occurs in response to a number of
“alarm signals” such as endotoxin, interferons and tumor
necrosis factors and largely is a consequence of NFκB
activationandHMGB-1acetylationatitsnuclearlocalisation
site [5, 6]. This induces vesicular sequestration and leads to
extracellular HMGB-1 release [1, 2]. In addition to active
secretion by activated monocytes/macrophages, passive dif-
fusion from necrotic cells may occur [1, 7].
Once released into the systemic circulation, receptor
binding of HMGB-1 to RAGE and toll-like receptors2 Mediators of Inﬂammation
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Figure 1: Course of HMGB-1 serum levels (ng/mL) from baseline
untilstudyday9(afterimmunotherapy)forGM-CSF(squares)and
placebo-treated (circles) individuals.
∗P ≤ .05,
∗∗P ≤ .01 (GM-
CSF-treated individuals); ##P ≤ .01 between the two groups at
the same day of assessment. Means ± SEM are given, paired and
unpaired samples t-test, as appropriate.
promotes chemotaxis, activates macrophages to release
cytokines(e.g.,interleukins,IL)/chemokines,inhibitsphago-
cytosis (e.g., of apoptotic neutrophils), and may facilitate
recognition and clearance of bacterial products [3, 4, 8–
11]. Clinically, however, this may support development of
acute lung injury, vascular leakage, tissue hypoperfusion,
and endothelial activation [12, 13]. Targeting of HMGB-
1 via, for example, speciﬁc neutralising antibodies seems
therefore appealing as it was shown in animal models that
this may protect rodents from lethal sepsis [14, 15]. Due to
a rather “wide” therapeutic window, blockade of HMGB-1 is
currently investigated in patients with “late” sepsis.
In addition to therapeutic approaches aiming to block or
neutralizespeciﬁcmediatorsinsepsis,modulationofcellular
immunity in an eﬀort to restore adaptive immune responses
was proposed. This was done as today many patients do not
die from an overwhelming septic burden in the initial phase
of the disease but rather in a state of immunologic anergy
from complications including severe secondary/nosocomial
infections [16–20]. Previously, we and others could demon-
strate that reversal of monocytic deactivation may be
achieved using measures of both immunostimulation (e.g.,
interferon-γ or granulocyte-macrophage colony stimulating
factor, GM-CSF) [21–23] and extracorporeal removal of
inhibitory factors [24]. This may especially be useful in the
later stages of sepsis [21–25].
It is currently unknown whether immunostimulatory
therapies aiming to restore monocytic function inﬂu-
ence systemic HMGB-1 levels. This seems of interest as
HMGB-1 release is known to occur from activated mono-
cytes/macrophages and may be a potential side eﬀect of such
immunostimulatory therapies. In the present analysis, we
aim to investigate the “in vivo interplay” between monocytic
function (assessed using monocytic HLA-DR expression
[mHLA-DR] and ex vivo TNF-alpha release) and HMGB-1
serum levels in patients with severe sepsis/septic shock and
sepsis-induced immunosuppression.
2.MaterialsandMethods
2.1. Study Population and Drawing of the Samples. 36
patients with severe sepsis or septic shock and monocytic
deactivation (deﬁned as a monocytic HLA-DR [mHLA-
DR] expression <8,000 antigens per cell) were included into
the analysis. The analysis presented here was a previously
planned subinvestigation of a placebo-controlled trial on
the clinical and immunological eﬀects of granulocyte-
macrophage colony stimulating factor (GM-CSF) in patients
with sepsis and immunoparalysis [22]. After inclusion and
randomization, all study patients were attributed to receive
either a daily subcutaneous injection of placebo (0.9% NaCl)
or GM-CSF (4μg/kg body weight) for 8 days. 8μg/kg body
weightGM-CSFwasgivenfromstudydays5to8intwocases
of unchanged mHLA-DR expression (mHLA-DR <15,000
antigens per cell at day 5). For assessment of HMGB-1 serum
heparinised plasma samples were drawn every other day
(at baseline, and study days 3, 5, 7, and 9) from central
venous catheters in the morning of each day. All samples
werestoredat −80degreesuntilanalysisandsamplesfromall
accessiblepatientsenteredtheanalysis.Twopatients’samples
from the overall analysis [22] were not available and did not
enter the analysis. All study patients received intensive care
unit (ICU) therapy in adherence to current international
guidelines. The study was approved by the local ethics
committee on human research (Ethikkomission der Charit´ e
Universit¨ atsmedizin Berlin, Germany) and was designed in
adherence to the Declaration of Helsinki. Written informed
consent was obtained from the patient or respective legal
representatives.
2.2. Detection of HMGB-1 Serum Levels and Measures of
Monocytic Immunity. HMGB-serum levels were assessed
using a sandwich ELISA technique (HMGB-1 ELISA kit
II, Shino-Test Corporation, Kanagawa, Japan) from 10μL
of heparinised plasma. As stated by the manufacturer, the
dynamic range of the HMGB-1 ELISA kit assay was 2.5–
82.0ng/mL. A sensitivity of 1ng/mL and an intra- and
inter assay coeﬃcient of variation <10% applied. Assessment
of monocytic function included measurement of ex vivo
LPS-induced TNF-α release from monocytes (heparinized
blood samples, diluted 1:10 with RPMI 1640 medium
(Biochrom KG, Berlin, Germany), 4 hours of stimulation
with 500pg/mL LPS (Milenia Ex Vivo Whole Blood Stim-
ulation kit, Milenia Biotec, Giessen, Germany) and stan-
dardized quantitative determination of the monocytic HLA-
DR expression (QuantiBRITE, BD Biosciences, Heidelberg,
Germany), as reported elsewhere [22, 26]. Cytokines were
determined using the IMMULITE automatic chemilumines-
cent immunoassay system (Siemens Medical Solutions, Bad
Nauheim, Germany). Assessment of respective indices was
performedinanaccredited(ISO15189certiﬁed)immunodi-
agnostic laboratory (Deptartment of Medical Immunology,
Charite University Medicine, Berlin, Germany).Mediators of Inﬂammation 3
Table 1: Characterisation of the study cohort.
control group treatment group Between group
(n = 18) (n = 18) P-value
gender (male) 15/18 (83%) 16/18 (89%) P = 1.0
age (years) 64 ± 15 64 ±14 P = .9
body weight (kg) 79 ±17 82 ±21 P = .6
days on ICU until inclusion 9 ±96 ±3 P = .25
baseline APACHE-II score 22.5 ±6.92 1 .3 ±6.0 P = .6
Table 2: Correlation table of systemic HMGB-1 levels with markers of monocytic function.
HMGB-1 serum level
baseline day 3 day 5 day 7 after therapy
(day 1) (day 9)
mHLA-DR expression
-o v e r a l lg r o u p P = .65 P = .61 P = .12 P = .31 P = .38
r = 0.08 r = 0.09 r = 0.27 r = 0.18 r = 0.16
- treatment
group
P = .98 P = .90 P = .98 P = .24 P = .73
r = 0.01 r =− 0.03 r = 0.01 r = 0.29 r = 0.09
- control group P = .49 P = .22 P = .97 P = .86 P = .80
r = 0.18 r = 0.31 r = 0.01 r =− 0.05 r = 0.07
ex vivo LP-Sinduced
TNF-α release
-o v e r a l lg r o u p P = .91 P = .97 P = .77 P = .57 P = .56
r =− 0.02 r =− 0.01 r = 0.05 r =− 0.10 r = 0.11
- treatment
group
P = .41 P = .50 P = .30 P = .46 P = .69
r =− 0.20 r =− 0.17 r =− 0.25 r =− 0.18 r =− 0.11
- control group P = .48 P = .16 P = .97 P = .89 P = .43
r = 0.18 r = 0.36 r =− 0.01 r =− 0.03 r = 0.21
2.3. StatisticalAnalysis. A lld at aar ep r e s e n t edasm e an± SD,
if not indicated otherwise. Analysis of variance (ANOVA)
with Fisher’s post hoc test, repeated measures ANOVA,
Student’s unpaired and paired t-tests, simple regression, and
chi-square test were used as appropriate. A P-value <. 05 was
considered signiﬁcant.
3. Results
3.1. Study Population. Samples from 36 patients (31 male,
aged 64 ± 14, APACHE II score 22 ± 6) with severe sepsis
or septic shock were assessed. For detailed patient character-
istics, please refer to Table 1 and [22]. Diﬀerences in baseline
patientcharacteristicswerenotnotedinregardtothefollow-
ing indices: etiology of sepsis, presence/distribution of gram
positive or gram negative/mixed infections, days on the ICU
until study inclusion, presence of shock/vasopressor need at
baseline, need for renal replacement therapy or mechanical
ventilation, and baseline disease severity (APACHE II [27]
and SOFA [28] scoring system, n.s. for all comparisons).
3.2. Course of HMGB-1 Serum Levels over the 9-Day Interven-
tion Interval. The course of HMGB-1 serum levels (ng/mL)
in both study groups is given in Figure 1. In the group
receiving immunostimulatory treatment, HMGB-1 serum
levels increased signiﬁcantly until study day 5 (Figure 1),
whereastheywereunchanged in placebo-treated individuals.
A signiﬁcant between-group diﬀerence was identiﬁed at
study day 5 (27.9±21.7v e r s u s1 1 .0±14.9ng/mL, (treatment
versus placebo group), P = .01). Signiﬁcant between-group
diﬀerences were not noted at any other point in time of
assessment. From study day 5 until study day 9, HMGB-
1 serum levels decreased in the treatment group. Before
(baseline)versusafterimmunotherapy(studyday9)HMGB-
1 serum levels were not found to diﬀer in both study groups
(both n.s., Figure 1).
3.3. Monocytic Immune Function and HMGB-1 Serum
Levels. We tested whether HMGB-1 levels correlate with
immunostimulation-induced changes in monocytic func-
tion. Two aspects of monocytic function were assessed using
standardized assays: antigen presentation (i.e., major his-
tocompatibility (MHC) class II surface expression, mHLA-
DR) and cytokine (TNF-α) release. Although a single
immunostimulatory treatment with subcutaneous GM-CSF
is known to signiﬁcantly increase both mHLA-DR expres-
sion and TNF-α release [22, 23], a consistent long-lasting
eﬀect on HMGB-1 serum levels was not noted (Figure 1).
Nevertheless, although a short- term increase in HMGB-
1 levels was noted at study day 5 (Figure 1), a correlation
of both mHLA-DR expression or ex vivo monocytic (LPS-
induced) TNF-α release with HMGB-1 serum levels was
not identiﬁed. A correlation between HMGB-1 levels and
markers of monocytic function was not noted at any point in4 Mediators of Inﬂammation
Table 3: Correlation table of systemic HMGB-1 levels with absolute numbers of immune cell subsets.
HMGB-1 serum level (overall samples analysis)
P-value r = 95% CI n =
Immune cell subsets
leukocytes .002 0.24 0.09–0.37 170
lymphocytes .001 0.25 0.10–0.39 170
CD4+ T-lymphoycytes .012 0.19 0.04–0.33 170
CD8+ T-lymphoycytes .025 0.17 0.07–0.35 170
B-lymphocytes .036 0.16 0.01–0.30 170
monocytes .001 0.25 0.10–0.39 170
NK cells .0003 0.27 0.13–0.41 170
time of assessment in any of the study groups (overall study
group, treatment group, or placebo group) over the 9-day
study interval (all n.s., except mHLA-DR with HMGB-1 at
study day 5, P = .12; Table 2).
3.4. Cytokines and HMGB-1 Serum Levels. Serum levels of
mediators which have mostly been referred to as “proin-
ﬂammatory” (tumor necrosis factor alpha [TNF-α], Inter-
leukin [IL]-6), and “anti-inﬂammatory” (IL-10), as well as
procalcitonin (PCT) levels were checked for correlations
with HMGB-1 levels in analyses including all samples.
Signiﬁcant correlations between HMGB-1 levels and the
aforementioned indices were not identiﬁed in the overall,
treatment, or placebo groups (all n.s., except TNF-α in the
subgroup of patients receiving treatment: P = .02, r = 0.24;
data not shown).
3.5. Immune Cell Subsets and HMGB-1 Serum Levels.
HMGB-1 levels were checked for correlations with the
absolutenumberofleukocytes,naturalkiller(NK)cells,total
number for lymphocytes, B-lymphocytes, T-lymphocytes
including CD4 positive and CD8 positive subsets, and
monocytes. Signiﬁcant correlations of HMGB-1 levels with
respective indices were identiﬁed (Table 3). However, when
HMGB-1 levels were adjusted for the total number of
leukocytes, the correlation between HMGB-1 levels and
markers of monocytic function (mHLA-DR expression, ex
vivo TNF-α release) and disease severity (APACHE II and
SOFA score) remained not signiﬁcant in the overall samples
analysis (all P>. 29).
3.6. Disease Severity (Clinical Scores) and HMGB-1 Serum
Levels over Time. We analysed whether HMGB-1 serum
levels reﬂect the course of disease severity in the study
population. Therefore, two established clinical scores [27,
28] were investigated whether they correlate with HMGB-
1 serum levels before and after immunotherapy (Table 4).
HMGB-1 serum levels were not found to correlate with
APACHE II and SOFA scores in any study group both
at baseline (study day 1) and after therapy (study day
9) (Table 4). These ﬁndings were conﬁrmed in an overall
samples analysis including samples from both day 1 and day
9 (HMGB-1 versus APACHE II: P = .71, r =− 0.05 [95% CI
–0.28–0.19], and HMGB-1 versus SOFA: P = .42, r =− 0.1
[95% CI –0.34–0.15], Table 4).
4. Discussion
Here we demonstrate that immunostimulatory treatment
using GM-CSF for sepsis-induced immunosuppression
induces a moderate but only transient increase in HMGB-
1l e v e l s( Figure 1). Except at study day 5 (after 4 GM-CSF
treatments), an association of systemic HMGB-1 levels with
indices of monocytic function (mHLA-DR expression, ex
vivo TNF-α release) was not observed (Table 2). Although
we identiﬁed moderate correlations between the absolute
number of circulating immune cell subsets and HMGB-
1( Table 3), the correlation between HMGB-1 levels and
markers of monocytic function were still not signiﬁcant
when the levels of HMGB-1 were adjusted for the number
of circulating leukocytes. Moreover, our data indicate that
HMGB-1 levels are not associated with disease severity
(assessed using the APACHE II and SOFA score, Table 4)
and serum levels of both “pro-” (TNF-α, IL-6) and “anti-
inﬂammatory” (IL-10) mediators in patients with sepsis-
induced immunosuppression. An association between the
levels of HMGB-1 and procalcitonin was also not noted.
Assessment of monocytic activation and monocytic
function is recognised a prerequisite for the design and
testing of new immunomodulatory therapies in sepsis [17,
19, 20, 22, 25, 26]. Standardized tests for the assessment
of monocytic HLA-DR expression and ex vivo LPS-induced
monocytic TNF-α release have recently been developed
and these biomarkers may help to guide immunotherapy
for sepsis [23, 26, 29]. In the analysis presented here,
we analysed samples from patients with sepsis-induced
immunosuppression receiving GM-CSF as a model inter-
vention to reconstruct monocytic immunity. In the past,
however,itwasdebatedwhetherthe“latemediator” HMGB-
1 reﬂects monocytic immunity and whether this may guide
immunomodulatory interventions in sepsis. Consequently,
as increased HMGB-1 serum levels were shown to reﬂect
adverse outcome from sepsis also, targeting of this late
proinﬂammatory mediator was proposed. From our data,
however, we conclude that HMGB-1 serum levels do not
reﬂect the course of monocytic immunity in patients
with sepsis-induced immunosuppression receiving a speciﬁc
immunotherapy for this clinical condition. We therefore
believe that this parameter should not be used as a primary
index for the monitoring of monocytic activation and/or
function. This may indeed be a relevant ﬁnding for future
immunomodulatory interventions. Moreover, we concludeMediators of Inﬂammation 5
Table 4: Correlation analysis of systemic HMGB-1 levels with indices of disease severity.
HMGB-1 serum level
baseline (day 1) after therapy (day 9) all samples (day 1 + 9)
APACHE II Score
-o v e r a l lg r o u p P = .053 P = .32 P = .71
r =− 0.32 r = 0.19 r =− 0.05
- treatment group P = .34 P = .16 P = .34
r =− 0.23 r = 0.36 r =− 0.23
- control group P = .09 P = .51 P = .09
r =− 0.43 r = 0.19 r =− 0.43
SOFA score
-o v e r a l lg r o u p P = .90 P = .38 P = .42
r =− 0.02 r =− 0.17 r =− 0.1
- treatment group P = .58 P = .12 P = .58
r =− 0.14 r =− 0.39 r = 0.14
- control group P = .82 P = .55 P = .83
r =− 0.06 r =− 0.17 r =− 0.06
that GM-CSF-induced reversal of monocytic deactivation
[22, 23] is not associated with a relevant increase in systemic
HMGB-1 levels.
A number of limitations of our analysis deserve further
discussion, among these being the fact that the observational
time interval is limited. Thus, the observational period could
have simply been too short to notice relevant changes in
HMGB-1serumlevels.Althoughwecannotruleoutthatthis
might have aﬀected our ﬁndings, we believe that this should
not have largely inﬂuenced our ﬁndings given the fact that
GM-CSF obviously induces a moderate but only transient
increase in HMGB-1 serum levels. Second, human IgG has
been reported to bind to HMGB-1 protein and may interfere
with ELISA detection [30]. This might have theoretically
inﬂuenced our measurements. Third, the scores that we used
as surrogate markers for clinical disease severity are not
evaluated to assess clinical disease severity in the later course
of the disease [27, 28]. Fourth, we demonstrate associations
rather than causal relationships in the analysis presented
here. Therefore, further ex vivo experiments seem necessary
to conﬁrm our ﬁndings. In addition, a number of questions
remain unanswered, among these the origin of the observed
temporary HMGB-1 serum levels increase (Figure 1). As
convincingly demonstrated in previous studies, however,
HMGB-1 release mostly occurs in response to immune cell
activation rather than by passive release following immune
cell apoptosis [2–8]. Thus, the observed short-term increase
in systemic HMGB-1 levels may have been caused by direct
GM-CSF-induced immunostimulatory eﬀects. However, this
remains a speculation as the underlying mechanisms need to
be elucidated in further studies.
In conclusion, our data demonstrate that HMGB-1
serum levels do not reﬂect monocytic function in patients
with sepsis-induced immunosuppression receiving immun-
omodulatory treatment. An association of HMGB-1 levels
with pro- and anti-inﬂammatory molecules or clinical
disease severity was not observed. We thus believe that
HMGB-1 serum levels should not be used as a primary index
for the monitoring of monocytic activation or function. This
might especially be of importance in subsequent immuno-
modulatory trials in sepsis.
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